文献速递肝病

TDF换用TAF后96周疗效与肾脏结局的真实世界研究

Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
PubMed 文献 · Hepatology · 2021-05-22

该研究纳入834例既往TDF治疗≥12个月的慢性乙型肝炎患者,换用TAF后随访96周。结果显示病毒抑制率和ALT复常率显著提高,eGFR总体稳定;基线eGFR<90的患者换药后eGFR不再下降,部分CKD分期改善。

要点

  • 换用TAF后病毒抑制率和ALT复常率显著提高,完全应答呈上升趋势。
  • 总体eGFR在换药后保持稳定,基线eGFR<90者换药后eGFR不再显著下降。
  • 换药96周时部分CKD 2期及3-5期患者分期改善。

核心结论

  • 换用TAF后病毒学应答和ALT复常持续改善,eGFR无显著变化。

研究设计与样本

  • 多中心真实世界队列研究,纳入834例既往TDF治疗≥12个月的慢性乙型肝炎患者,换用TAF后随访96周。

主要发现

  • 换药后病毒抑制率(P < 0.001)和ALT复常率(P = 0.003)显著提高,完全应答呈上升趋势(Ptrend = 0.004)。
  • 总体eGFR趋势(Ptrend > 0.44)和平均eGFR(P > 0.83)保持稳定。
  • 基线eGFR < 90者,TDF治疗期间平均eGFR显著下降(P = 0.029),换用TAF后不再下降(P = 0.90)。
  • 第96周时,换药时CKD 2期患者中21%(55/267)改善至1期,CKD 3-5期患者中35%(30/85)改善至2期、1.2%(1/85)改善至1期。

关键数值与推荐

  • 病毒学抑制定义为HBV DNA < 20 IU/mL。
  • 生化应答定义为ALT < 35/25 U/L(男/女)。
  • 完全应答定义为病毒学抑制联合生化应答。
  • CKD分期基于eGFR(毫升/分钟/1.73平方米)。

临床怎么用

  • 对于TDF治疗期间肾功能下降的慢性乙型肝炎患者,换用TAF可稳定肾功能并改善部分患者CKD分期。
  • 换用TAF后应继续监测病毒学和生化应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Real-world data for treatment effectiveness and renal outcomes in chronic hepatitis B (CHB) patients who were switched to the new and safer prodrug tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) are limited. Therefore, we aimed to evaluate treatment and renal outcomes of this population. APPROACH AND RESULTS: We analyzed 834 patients with CHB previously treated with TDF for ≥12 months who were switched to TAF in routine practice at 13 US and Asian centers for changes in viral (HBV DNA < 20 IU/mL), biochemical (alanine aminotransferase [ALT] < 35/25 U/L for male/female), and complete (viral+biochemical) responses, as well as estimated glomerular filtration rate (eGFR; milliliters per minute per 1.73 square meters) up to 96 weeks after switch. Viral suppression (P < 0.001) and ALT normalization (P = 0.003) rates increased significantly after switch, with a trend for increasing complete response (Ptrend = 0.004), while the eGFR trend (Ptrend > 0.44) or mean eGFR (P > 0.83, adjusted for age, sex, baseline eGFR, and diabetes, hypertension, or cirrhosis by generalized linear modeling) remained stable. However, among those with baseline eGFR < 90 (chronic kidney disease [CKD] stage ≥2), mean eGFR decreased significantly while on TDF (P = 0.029) but not after TAF switch (P = 0.90). By week 96, 21% (55/267) of patients with CKD stage 2 at switch improved to stage 1 and 35% (30/85) of CKD stage 3-5 patients improved to stage 2 and 1.2% (1/85) to stage 1. CONCLUSIONS: Overall, we observed continued improvement in virologic response, ALT normalization, and no significant changes in eGFR following switch to TAF from TDF.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Toyoda H, Leong J, Landis C, et al. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. Hepatology. 2021. PMID: 33706421. doi:10.1002/hep.31793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。